Approximately 50% of cutaneous melanomas (CM) harbor an activating mutation in the B-Raf protooncogene (BRAF), predominantly a substitution of valine to glutamine in codon 600 (i.e., BRAFV600E), conferring a constitutive activation of the mitogen-activated protein kinase (MAPK)-pathway, which stimulates tumor cell proliferation and survival [1]. The gene discussed is WNK2; the disease is cutaneous mastocytosis.